The Power of Collaboration
The 2016 Access to Medicine Index was just released and one of our key partners, Johnson & Johnson, was ranked #2 among 20 pharmaceutical companies for their efforts to improve access to medicines, build capacity and improve health and well-being for patients everywhere.
Diana Kabuswe, Makululu Health Facility Maternal Child Health Coordinator showing a mother the correct dosage for medicine.
Ensuring the broadest possible access to medicines that their scientists work hard to discover and develop is a key part of Johnson & Johnson’s global public health strategy.
This biennial Index provides an important independent assessment of the industry’s ongoing commitment to expand access to medicines, vaccines, and diagnostics for patients most in need.
This year’s Index focused on efforts to address 50 conditions and diseases – including communicable and non-communicable diseases, neglected tropical diseases and maternal and neonatal health conditions – in 107 low- and middle-income countries that represent the highest burden of disease and inequality.
A family in Haiti
Johnson & Johnson remain motivated by the progress they have made, the innovations they are piloting, and the opportunities they see. They have promised to continue evolving and expanding their our efforts to discover, develop, and deliver lifesaving medicines to reach as many patients as possible.
This recognition for Johnson & Johnson is a reflection of the exceptional collaboration we enjoy with partners around the world, and we would like to take this opportunity to express our sincere thanks for their ongoing support as we work together to improve global health outcomes.
Right now, Johnson & Johnson is matching every donation you make towards our goal of providing safe water filtration systems to families in Haiti impacted by Hurricane Matthew, helping to prevent infectious diseases like cholera.
Join us.